+ Watch SNY
on My Watchlist
A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
Aging population (especially in Europe) will continue to increase dependency on prescription medications, also doing some great things with R&D.
Good year for health care...even in Europe
High Volume Breakout on 02/08/13
Lantus is going to get crushed by biosimilars. Would reevaluate if I saw some more interesting Growth moves
EPS $6.90 TP $60
Dodge & Cox International Stock Fund DODFX
Attach "Europe based" to nearly any company in this fall of 2012, and expect a measurable price discount. Add to that SNY's history of drug development and management coupled with the change growing population of drug consumers (read, more baby boomers aging), and you have a winner.
Above average drug portfolio. Growth of existing and new products should more than make up for patent expirations.
Buffett favorite of mine. Good current price. Cash generating cow.
no innovation, big patent cliff with Plavix/Lovenox/Lantus...nothing to replace them. Stock has done little over the past few years.
sells for 8% less than what Buffett paid.
It's yielding 3.57% and 5 stars
drug production and pipeline will boost earnings
India based biotech in under-represented market
Dividend makes is "safer" in the short run but with pipeline and genzyme long term also looks good
This stock is a Cramer favorite with a decent 3.8% yeild. Cramer believes this company has a low valuation, and is an accidental high yeilder. Ken Fisher of Fisher Asset Management recently increased holdings to over 14,750,000 shares.
Strong pipeline and nice dividend make SNY a compelling buy at this price.
want 2 get it on the down turn. down 4% strong co.
A good defensive stock with a good divi.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions